AttardLab highlighting #TheraP ctDNA biomarkers. The figure speaks for itself. A candidate predictive biomarker. Don't miss Edmond Kwan poster presentation tomorrow. Super research from Alex Wyatt ANZUP Ian Davis Arun Azad ASCO #ASCO24

Our latest paper on ctDNA detection using WGS is now published in European Urology. This WGS-based approach simplifies clinical workflows by eliminating the need for personalized assays. Read the paper here : doi.org/10.1016/j.euru…

🎉 The dream is coming true! I'm thrilled to share that I will be returning to Montreal in Jan2025 to open my lab at Centre de recherche du CHUM and École de technologie supérieure! We'll be dedicated to advancing precision oncology, developing cutting-edge omic tools to enhance patient care. 🧬 #newPI

Extremely excited to share our recent work in Nature Communications. UBC press release about the work can be found here: news.ubc.ca/2024/06/using-…

So excited to see Morgan Roberts join faculty and #bladdercancer team Vancouver Prostate Centre and UBCUrology - looking forward to many innovative discoveries and watching your rapid upward trajectory!

Big breakthroughs to come from A/Prof Morgan Roberts - a new PI in our department, and with innovative ideas around the important intersection between immunology and bladder cancer.

New paper from the lab Vall d’Hebron Institute of Oncology (VHIO) is out in Cancer Cell: dual DNA/mRNA profiling from circulating EVs in #prostatecancer liquid biopsies Team-science work led by our own Irene cell.com/cancer-cell/fu…

VCHRI PhD candidates Cameron Herberts & Cristina Rubino are the 2024 Top Graduating Doctoral Student Award recipients. Their projects will advance prostate cancer therapy & support stroke rehabilitation. Cameron Herberts Cristina Rubino

The West Coast Dream Team is thrilled to share deep whole genome sequencing, whole genome 5mC and 5hmC, transcriptomics, ATAC-seq, and now Hi-C all in a matched cohort of metastatic prostate cancer patients. Thanks to @pcf_science for supporting this resource!

Thank you Bladder Cancer Advocacy Network for the support! We're really excited to get started! I'm also v happy to have such fantastic colleagues for this project including Bernie Eigl, Peter Black, David Takeda, Gillian Vandekerkhove

Super interesting thread (and paper) on TP53 and whole-genome doubling in lung cancer. Can't help thinking about parallels to advanced prostate and bladder cancer where both TP53 & WGD are common, mixed responses to targeted therapy v common, and TP53mut is prognostic.

We keep ignoring CHIP (clonal hematopoiesis of indeterminate potential= mutations in our blood stem cells) even though it is no longer "indeterminate." A key marker for risk of cardiovascular events and blood cancers. It should be routinely assayed in older adults.

NEW! Infographic of recommendations for optimising samples for biomarker testing in lung, prostate & gastric cancer With experts Bibeau Frédéric and Alex Wyatt Association for Molecular Pathology endorsed Download our second infographic poster here: ow.ly/OoQb50ST9Fe #MedEd #PrecisionOncology

🧬Excited to share highlights from our latest publication demonstrating preservation of clinical utility with whole genome sequencing (WGS) data generated from routine FFPE cancer biopsies! 🧵#CancerGenomics Serena Nik-Zainal Early Cancer Institute, University of Cambridge University of Cambridge Medical Genetics nature.com/articles/s4146…

Great to have Ewan Gibb join our ranks. More genomics, bioinformatics, biomarker dev, and GU cancer biology insights on the way!

Exited to share the first results from the TOMBOLA trial presented at #ESMO24 by Jørgen Bjerggaard. We used tumor informed (WES; ddPCR) ctDNA analysis to guide Atezolizumab treatment after cystectomy using longitudinally collected blood samples. Key findings: •CtDNA-negative

Yesterday Emily Grist showed out groundbreaking #Decipher outcome with Decipher score predictive of docetaxel benefit. A first Veracyte, Inc. Elai Davicioni The ICR MRC Clinical Trials Unit at UCL #Stampede AttardLab

⚡️LBA - INSPIRE: Ph 2 trial of Nivo 3mg/kg + Ipi 1mg/kg in molec select pts w/ mCRPC UroToday.com #ESMO24 niven mehra 📌n=69 📌DCR > 6 months: 38% (95% CI 27-51) -- >22% for +ve trial - MMRd: 81% - hTMB: 25% - CDK12i: 19% - BRCAm: 15% 📌 Med rPFS: 4.0 mo (95% CI, 3.5 to 12.0);

💡Will #ctDNA serve as a treatment response biomarker in metastatic cancers? Here’s a thorough evaluation in Clinical Cancer Research from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond. 👉 doi.org/10.1158/1078-0…

Alex Wyatt Clinical Cancer Research Elena Garralda Lars Dyrskjøt Hillary Andrews, PhD Sofie Tolmeijer Elisabeth de Vries CCTG BC Cancer UBC Medicine Vancouver Prostate Centre Agree, this will be so informative to correlate with standard imaging criteria. First demonstrating enough 🧬 shed to be positive, and then 🧬 clearance can be a powerful surrogate for ORR. Low shed tumors like RCC or sarcoma might not be best candidates.